Disease · MONDO_0006604
Comparisons in its trials34
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 34
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Oracea® as Monotherapy vs Oracea® as add-on Therapy: Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear) | 616 of 1,197 | 106 of 224 | 1,421 | NCT00892281 | Trial comparisons |
| Oracea® as Monotherapy vs Oracea® as add-on Therapy: serious adverse events | 5 of 1,196 | 0 of 224 | 1,420 | NCT00892281 | Trial comparisons |
| Azelaic Acid Foam, 15% (BAY39-6251) vs Vehicle Foam: serious adverse events | 3 of 483 | 4 of 478 | 961 | NCT01555463 | Trial comparisons |
| FMX103 1.5% vs Vehicle Foam: deaths from any cause | 0 of 514 | 0 of 257 | 771 | NCT04608500 | Trial comparisons |
| FMX103 1.5% vs Vehicle Foam: serious adverse events | 1 of 514 | 2 of 257 | 771 | NCT04608500 | Trial comparisons |
| FMX103 1.5% vs Vehicle Foam: deaths from any cause | 0 of 494 | 1 of 256 | 750 | NCT03142451 | Trial comparisons |
| FMX103 1.5% vs Vehicle Foam: serious adverse events | 2 of 494 | 3 of 256 | 750 | NCT03142451 | Trial comparisons |
| Azelaic Acid Foam, 15% (BAY39-6251) vs Vehicle Foam: serious adverse events | 1 of 198 | 3 of 203 | 401 | NCT01025635 | Trial comparisons |
| Ivermectin 1% Cream + Doxycycline 40 mg MR Capsules vs Ivermectin 1% Cream + Oral Placebo Capsules: deaths from any cause | 0 of 135 | 0 of 138 | 273 | NCT03075891 | Trial comparisons |
| Ivermectin 1% Cream + Doxycycline 40 mg MR Capsules vs Ivermectin 1% Cream + Oral Placebo Capsules: serious adverse events | 1 of 135 | 1 of 138 | 273 | NCT03075891 | Trial comparisons |
| DFD-29 vs Doxycycline 40 mg: IGA Treatment Success Compared to Doxycycline. | 74 of 123 | 39 of 125 | 248 | NCT05343455 | Trial comparisons |
| DFD-29 vs Doxycycline 40 mg: IGA Treatment Success Compared to Doxycycline. | 79 of 122 | 56 of 121 | 243 | NCT05296629 | Trial comparisons |
| Azelaic Acid (Finacea, BAY39-6251) Plus Doxycycline (Oracea) vs Metronidazole (Metrogel) Plus Doxycycline (Oracea): serious adverse events | 0 of 106 | 1 of 101 | 207 | NCT00855595 | Trial comparisons |
| DFD-29 vs Placebo: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. | 74 of 123 | 22 of 82 | 205 | NCT05343455 | Trial comparisons |
| DFD-29 vs Placebo: Clinician's Erythema Assessment (CEA) Change Compared to Placebo. | 30 of 123 | 10 of 82 | 205 | NCT05343455 | Trial comparisons |
| DFD-29 vs Placebo: Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo. | 79 of 122 | 25 of 80 | 202 | NCT05296629 | Trial comparisons |
| DFD-29 vs Placebo: Clinician's Erythema Assessment (CEA) Compared to Placebo. | 39 of 122 | 11 of 80 | 202 | NCT05296629 | Trial comparisons |
| Azelaic Acid Foam, 15% (BAY39-6251) vs Vehicle Foam: serious adverse events | 0 of 41 | 0 of 42 | 83 | NCT00617903 | Trial comparisons |
| Clindamycin/Tretinoin Gel vs Placebo Gel: serious adverse events | 0 of 43 | 0 of 40 | 83 | NCT00823901 | Trial comparisons |
| DFD-04 Ointment vs Placebo Ointment: Number of Subjects With Investigator's Global Assessment (IGA) Success | 3 of 38 | 2 of 23 | 61 | NCT02828241 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006604/comparisons